Zepbound for Sleep Apnea via Telehealth: The Home Sleep Test Step

To get Zepbound covered for sleep apnea, most insurers want proof of moderate to severe obstructive sleep apnea, meaning an apnea-hypopnea index (AHI) of 15 or more on a sleep study, plus a BMI of 30 or higher. A home sleep apnea test ordered through telehealth can supply that proof for many adults, but not for everyone. The study report, not the weight-loss intake, is what moves the prior authorization.

Why the sleep apnea indication changes coverage

The FDA approved Zepbound for OSA on Dec. 20, 2024, calling it the first drug treatment option for certain patients with the condition. The Zepbound prescribing information (revised August 2026) lists two separate indications: chronic weight management, and treatment of moderate to severe OSA in adults with obesity.

That second indication matters because many plans treat weight loss and sleep apnea differently. A plan that excludes weight-loss drugs may still review Zepbound for OSA as treatment of a diagnosed disease. Medicare works the same way: CMS's GLP-1 Bridge provider page says beneficiaries with moderate to severe OSA "are eligible to receive GLP-1s through their Part D plan" and should continue to obtain them that way.

Eligible for review is not the same as covered. Whether your specific plan pays depends on its formulary and criteria, which is why the documentation step below matters.

What payers ask for

Criteria vary by plan, but published policies share a core. The table compares three public examples.

Sources: Cigna coverage policy IP0816, Centene clinical policy CP.PMN.298, TRICARE Wegovy/Zepbound PA form. Your plan's criteria may differ.

One detail is easy to miss. Centene's policy requires members with type 2 diabetes to have tried other GLP-1s first, unless they cannot take them.

The thresholds match how the American Academy of Sleep Medicine's 2026 Zepbound fact sheet for clinicians describes the population the drug is for: adults with obesity (BMI of 30 or more) and moderate to severe OSA (AHI of 15 or more).

How a home sleep apnea test fits into telehealth

A home sleep apnea test (HSAT) is a simplified sleep study you wear in your own bed. It records fewer signals than an in-lab study, such as airflow and blood oxygen. In a telehealth setting the sequence usually looks like this:

1. Clinical evaluation. A clinician licensed in your state takes a sleep history: snoring, witnessed pauses, daytime sleepiness, other conditions and medications.
2. The order. If home testing fits, the clinician orders it. A device is mailed or picked up.
3. The test. You wear it for one or more nights, then return it or upload the data.
4. Scoring and interpretation. The recording is scored, and a qualified clinician interprets it and issues a report with your event index and severity.
5. Treatment plan and PA. If the report shows moderate to severe OSA and you meet the BMI threshold, the prescriber can submit a prior authorization with the report attached.

The AASM's clinical practice guideline on diagnostic testing for adult OSA says testing should be performed "in conjunction with a comprehensive sleep evaluation and adequate follow-up." It also says questionnaires and prediction tools should not be used to diagnose OSA without a sleep study, so an online screener alone will not satisfy a payer.

AHI vs. REI

Home test reports may list a respiratory event index (REI) instead of an AHI. Cigna's policy explicitly accepts either an AHI or an REI of 15 or more. Check whether your plan's wording does.

When a home test isn't the right tool

The 2017 AASM guideline recommends home testing, with a technically adequate device, for uncomplicated adults whose signs and symptoms indicate increased risk of moderate to severe OSA. It defines that as excessive daytime sleepiness plus at least two of: habitual loud snoring, witnessed apnea or gasping or choking, or diagnosed hypertension.

It recommends in-lab polysomnography instead for people with:

• Significant cardiorespiratory disease
• Possible respiratory muscle weakness from a neuromuscular condition
• Awake or suspected sleep-related hypoventilation
• Chronic opioid use
• A history of stroke
• Severe insomnia

The guideline also says that if a single home test is negative, inconclusive or technically inadequate, polysomnography should follow rather than a second home test. A telehealth service that only offers home testing should have a plan for those cases, usually a referral to a local sleep lab.

Medicare: why the Bridge is the wrong door for OSA

The Medicare GLP-1 Bridge offers a $50 copay for weight management through Dec. 31, 2027, but it is not for people with sleep apnea. Medicare.gov lists people with moderate to severe sleep apnea, type 2 diabetes or fatty liver disease as not eligible and says their Part D plan might cover GLP-1s instead. CMS's provider page tells prescribers to route those patients through the Part D plan.

That means a Medicare patient with OSA faces the plan's own formulary, prior authorization and cost-sharing, not the flat $50. On the testing side, Medicare's national coverage determination for OSA sleep testing covers unattended home tests of qualifying device types for people with clinical signs and symptoms of OSA, and denies tests not ordered by a treating physician or qualified practitioner.

Questions to ask a telehealth platform first

Sources: AASM diagnostic testing guideline; AASM Zepbound fact sheet.

A hypothetical, clearly labeled

Hypothetical scenario, not a real patient: An adult with a BMI of 34, loud snoring and daytime sleepiness has commercial insurance that excludes weight-loss drugs. A telehealth sleep clinician orders a home test, which reports an REI of 22. The plan's policy accepts an REI of 15 or more, so the prescriber submits a prior authorization for Zepbound under the OSA indication with the report attached. If the same person used opioids daily for chronic pain, the guideline would point toward an in-lab study instead.

After approval: don't drop your CPAP on your own

The AASM fact sheet says Zepbound should be part of comprehensive OSA care, "not as a replacement for PAP," and that many patients will still need PAP or other therapies. It suggests considering a repeat home test or polysomnogram once weight stabilizes. Renewal criteria in the policies above also look for improvement, so keep your follow-up appointments and records.

Where this guide stops

This guide covers the coverage and testing process as of October 2026. It does not compare Zepbound with CPAP, and it cannot tell you whether you have sleep apnea or which test you need. Plan criteria change, so check your own plan's policy. For diagnosis and treatment decisions, talk to a sleep clinician or your prescriber.

Sources

1. FDA: FDA approves first medication for obstructive sleep apnea (Dec. 20, 2024)
2. Zepbound (tirzepatide) prescribing information, Eli Lilly, revised 08/2026
3. American Academy of Sleep Medicine: Zepbound provider fact sheet (2026)
4. Kapur VK, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea. J Clin Sleep Med. 2017
5. Cigna: Coverage policy IP0816, Weight loss – Zepbound
6. Centene: Clinical policy CP.PMN.298, Tirzepatide (Zepbound)
7. TRICARE prior authorization request form for Wegovy/Zepbound, US Family Health Plan version (Martin's Point Health Care, undated)
8. CMS: Medicare GLP-1 Bridge, information for providers
9. Medicare.gov: Weight loss drugs
10. CMS: National coverage determination, Sleep Testing for Obstructive Sleep Apnea (240.4.1)

Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.